| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802332406028 | 233240602 | REBIF INJ.SOL 6MU/0,5ML PF.SYR BTx3PF.SYRx0,5ML | 160.16 | 168.00 | 203.01 |
| 05/2018 | 2802332408022 | 233240802 | REBIF INJ.SOL 12 MU /0,5ML PF.SYR BTx3PF.SYRSx0,5ML | 176.28 | 184.92 | 223.46 |
| 05/2018 | 2802332410018 | 233241001 | REBIF INJ.SOL 66MCG (22MCG/0,5ML)/1,5ML CARTRIDGE BTx4 CARTRIDGES | 620.73 | 630.04 | 714.59 |
| 05/2018 | 2802332411015 | 233241101 | REBIF INJ.SOL 132MCG (44MCG/0,5ML)/1,5ML CARTRIDGE BTx4 CARTRIDGES | 653.97 | 663.78 | 752.85 |
For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum
Interferon beta binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon beta binds more stably to type I interferon receptors than interferon alpha.
10 hrs
* 33-55 L/hour [Healthy SC injection of 60 mcg]